ArticleBMJ open2019

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.

Maria-Luisa Schubert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.